All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub

Brought to you by Scientific Education Support

Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My ALL Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View ALL content recommended for you

EHA 2022

Share:

Jun 8, 2022

X post image

21 Nov 2022

Re-watch this:
During #EHA2022 Congress Anita Rijneveld discussed if adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
👉 https://t.co/Zxk1OB2xpP #ALLsm @ErasmusMC

X post image

12 Jul 2022

💬 #EHA2022 | Anita Rijneveld discusses if adding blinatumomab to frontline therapy improves survival outcomes for adults with B-ALL? Rijneveld also speaks about the D-ALBA trial & blinatumomab combination therapies

👉 https://t.co/Zxk1OB2xpP 👈

#leusm #leukemia @ErasmusMC

X post image

5 Jul 2022

🎧 During #EHA2022, we spoke with @CoolsJn, @vib_ccb. We asked, What is the cellular origin of acute lymphoblastic #leukemia

Listen to the 12 minute interview here!
👉 https://t.co/8QMkZGrpmp 👈

#ALLsm #leusm

X post image

21 Jun 2022

📢For all our #EHA2022 live coverage check out our twitter moments! And keep an eye out for further articles and videos on the ALL Hub!

#leusm #leukemia #ALLsm

https://t.co/tiemxlJuqU

X post image

14 Jun 2022

RT @sghorashian: Was pleased to present our data on the CARPALL study #EHA2022 with dual targeting of CD19 & CD22. Fast off rate CD19CAR a…

X post image

13 Jun 2022

CONGRESS #EHA2022 | @sghorashian @GreatOrmondSt presented phase I study results of AUTO1/22 in heavily pretreated pts with R/R B-ALL. N=11. Dual CD19/22 targeting CART showed acceptable safety with robust expansion & early efficacy. 1 month post-infusion CR/CRi=88% #allsm #leusm

X post image

12 Jun 2022

We hope you’ve enjoyed keeping up with our live #EHA2022 congress updates! 🎓

Keep an eye on our socials for post-congress summaries and key insights! 📲

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

CONGRESS #EHA2022 | Barbora Vakrmanova Medicine and Motol University Hospital presented post-daratumumab administration treatment & diagnosis challenge(N=6). Due to steric hindrance between daratumumab & mAbs conventional anti-CD38 mAbs unable to bind leukemia cells #allsm #leusm

X post image

12 Jun 2022

CONGRESS #EHA2022 | @NicholasShortMD @MDAndersonNews reports on a phase II study of ponatinib + blinatumomab in pts with either ND Ph+ALL, R/R Ph+ALL or CML. N=55,
CR/CRi: ND ALL pts=96%, R/R Ph+ALL pts=92%, CML pts=83% #allsm #leusm #leukemia

X post image

12 Jun 2022

CONGRESS #EHA2022 | Renato Bassan, Ospedale dell'Angelo reports on GIMEMA LAL 1913 phase II study of pegaspargase in pts with Ph- ALL/LBL. N=203, median follow-up=38.7 months, CR=91%, 3yr DFS=63%, OS=67%, EFS=58% #allsm #leusm #leukemia

X post image

12 Jun 2022

CONGRESS #EHA2022 | Susana Rives @SJDbarcelona_es presented ELIANA phase II study results of tisagenlecleucel in heavily pretreated pediatric and adult pts with R/R B-ALL. N=97, ORR=82%, 5 yr RFS=44%, median OS not reached #allsm #leusm #leukemia

X post image

12 Jun 2022

CONGRESS #EHA2022 | Giovanni Fernando Torelli @SapienzaRoma presented GIMEMA LAL 2013 phase I study of autologous NK cells in pts with Ph+ B-ALL. N=6. Adoptive immunotherapy with NK cells was safe, well-tolerated with lasting antileukemic activity & disease control #allsm #leusm

X post image

12 Jun 2022

CONGRESS #EHA2022 | Peihua Lu from Hebei Yanda Lu Daopei Hospital presented a phase I study of KO7CAR T-cells in pts with R/R T-cell malignancies (T-ALL, LBL, MPAL). N=15, On day 28 CR=100% (all MRD negative), manageable safety profile #allsm #leusm #leukemia

X post image

12 Jun 2022

RT @lymphomahub: CONGRESS #EHA2022 LBA:
Isabelle van Zeventer @umcg, presents the largest study on clonal evolution in the general populati…

X post image

12 Jun 2022

CONGRESS #EHA2022 | Davide Lazzarotto from Azienda Sanitaria Universitaria Friuli Centrale presented a retrospective analysis of CAMPUS-ALL trial of adult pts with MPAL diagnosed & treated in the last 10 yrs. N=77. CR=62% (42% MRD negative), 5 yr OS & DFS=43% & 39% #allsm #leusm

X post image

12 Jun 2022

It’s the last day of EHA!

Don’t miss out on closing interviews, key insights, and live updates!

Sessions covered👇

- Novel insights into the treatment of ALL
- Immune response and infection in hematology – Clinical

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

CONGRESS #EHA2022 | Francesco Muriano @AC_AOU_FedII reported results of blinatumomab+DLI in 3 MRD-positive patients after allogeneic HSCT. 2 pts reached stable MRD undetectable status and 2 subsequently developed CNS relapse, none received CNS prophylaxis post-HSCT #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | Yang finally outlined the clinical implementation of pharmacogenomics #leusm #allsm

X post image

10 Jun 2022

#EHA2022 | Yang discussed hepatotoxicity in patients receiving #ALL therapy, which can occur in all treatment phases. Liver toxicity was more likely in pts with UGT1A1 and PNPLA3 gene mutations, and TPMT mutations were associated with ALT during maintenance only #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | A second example was asparaginase, which can induce immunological immune reactions, particularly hypersensitivity, which varies by formulation, and HLA is a top genetic risk factor for this #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | @Junjyang talked about thiopurines and their association with dose limiting myelosuppression, and presented data demonstrating two loci associated with resistance to 6-MP, TPMT and NUDT15, and how this affects therapeutic dosing #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | @Junjyang discussed pharmacogenomics in ALL treatment and how to use genomics for precision medicine #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | Schmiegelow discussed the risk factors for osteonecrosis, highlighting how older age affects the time to onset #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | ASNase associated pancreatitis does not occur at first exposure, but accumulates with dose, and increases with risk in ages 6 and above. The risk of second episode with re-exposure is 50% and there is no correlation between severity of 1st and 2nd episode #allsm

X post image

10 Jun 2022

#EHA2022 | Truncating ASNase increases relapse rates in ALL (70-80% higher than pts who received full treatment) demonstrating the importance of this therapy. Premedication prior to asparaginase treatment reduces hypersensitivity #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | Schmiegelow discussed preventive measures for thrombotic events, highlighting the effect of low molecular weight heparin in reducing the risk of TEs #allsm #leusm

X post image

10 Jun 2022

#EHA2022 | Kjeld Schmiegelow discussed toxicities with asparaginase treatment in #ALL, firstly highlighting how one in four patients will experience an asparaginase related toxicity leading to treatment truncation, with clinical hypersensitivity the most common event #leusm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | He concluded that short- and middle-term toxicity profiles are known enough to training HCPs and specific and tight hospital organization are needed to allow safe treatment. #allsm #leusm

X post image

10 Jun 2022

CONGRESS| #EHA2022 | @Cchabannon, @univamu, on managing CAR T cell toxicities:
- Short-term AEs in different CAR T cells, different indications, and registration studies vs real-world data,
- Reporting of CRS and ICANS is critical
- Middle-term and long term AEs #leusm #allsm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | Michel Sadelaine, @MSKCancerCenter, discussed if coordinated CAR signalling and epigenetic programming would prolong the productive lifespan of CAR T cells with a focus on TET2 and SUV39h1 disruption #leusm #allsm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | Outcomes from different studies investigating different CAR T cell constructs #lymphoma #lymsm #allsm #leusm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | @drclaireroddie, @UCL @uclcancer @UCLH gives a talk on different engineering methods in dual targeting CAR, and shared outcomes in #all and #lymphoma. She emphasized the need for advanced preclinical evaluation to select best construct #leusm #allsm

X post image

10 Jun 2022

The @ALL_Hub will be virtually covering sessions on disease biology and translational research, the value of MRD, and CAR T-cell therapies.

Stay tuned for live updates, key insights, and interview coverage!

#EHA2022 #medicalcongress #cancerawareness

X post image

7 Jun 2022

The @ALL_Hub_ will be covering the EHA 2022 Congress!

The first ever hybrid @EHA_Hematology congress, where we will be attending online and in Vienna!

Keep an eye on our socials for live updates throughout the day! 🗣💻

#EHA2022 #medicalcongress #cancerawareness

X post image

6 Jun 2022

To help navigate the exciting content being presented at the #EHA2022 Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in #ALL. Find it here 👇

https://t.co/pxIeJssfTL

pan> </span

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022 European Hematology Association

Newsletter

Subscribe to get the best content delivered to your inbox